ea0020p244 | Bone/Calcium | ECE2009
Anastasilakis Athanasios
, Polyzos Stergios
, Avramidis Avraam
, Papatheodorou Athanasios
, Terpos Evagellos
Teriparatide (TPTD recombinant human parathyroid hormone 134) markedly increases bone mineral density (BMD) and reduces fracture risk. Sequential treatment with an antiresorptive agent is believed to preserve or further increase BMD. Strontium ranelate (SR) is thought to uncouple bone remodeling resulting in increased BMD and reduced fracture risk. In this prospective study, we aimed to evaluate the effect of SR on BMD in women with established osteoporosis previo...